MiNA Therapeutics picks up another saRNA research deal

11 May 2021

Adding to a deal with AstraZeneca (LSE: AZN) in 2020 and one with Servier earlier this year, UK-based RNA activation therapeutics pioneer MiNA Therapeutics has today announced a global research collaboration with US pharma major Eli Lilly (NYSE: LLY) to develop novel drug candidates using MiNA’s proprietary small activating RNA (saRNA) technology platform.

Under the terms of the accord, privately-held MiNA will utilize its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly’s key therapeutic focus areas. Lilly will be responsible for pre-clinical and clinical development of candidates and will retain exclusive commercialization rights for any products resulting from the collaboration.

Financial terms of the accord

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK